Download
Download by
Scanning QR Code
  • Download app

    Download app

  • Online Inquiry

    Log in to access Online Inquiry
+
Congratulations
You've successfully got advanced quotes worth 5000 HKD
Download APP >>
Multi-dimentional Analyses
Company Valuation Capital Tracking Short Selling Data
Futubull > Quotes > REPL Replimune > Detailed Quotes

REPL Replimune

Watchlist
17.480
+0.030+0.17%
Close 06/30 16:00 ET
17.48000.00%
Post Mkt Price 06/30 16:01 ET
Giving away premium quotes worth 5000 HKD/year to unlock more data
Get NOW
High
17.670
Open
17.330
Turnover
2.12M
Low
16.670
Pre Close
17.450
Volume
121.72K
Market Cap
857.74M
P/E(TTM)
Loss
52wk High
39.840
Shares
49.07M
P/E(Static)
Loss
52wk Low
13.050
Float Cap
496.53M
Bid/Ask %
0.00%
Historical High
54.850
Shs Float
28.41M
Volume Ratio
0.38
Historical Low
8.580
Dividend TTM
--
Div Yield TTM
10
P/B
2.09
Dividend LFY
--
Div Yield LFY
57.21%
Turnover Ratio
0.43%
Amplitude
5.73%
Avg Price
17.385
Lot Size
1
Float Cap
496.53M
Bid/Ask %
0.00%
Historical High
54.850
Shs Float
28.41M
Volume Ratio
0.38
Historical Low
8.580
Dividend TTM
--
P/B
2.09
Dividend LFY
--
Turnover Ratio
0.43%
Amplitude
5.73%
Avg Price
17.385
Lot Size
1
Price Forecast

No Data

News

Comment

Company Overview More
Replimune Group, Inc., a biotechnology company, develops oncolytic immuno-gene therapies to treat cancer. It uses its proprietary Immunotherapy platform to design and develop product candidates that are intended to activate the immune system against cancer. The company’s lead product candidate is RP1, a selectively replicating version of herpes simplex virus 1, which is in Phase I/II clinical trials for a range of solid tumors; and that is in Phase II clinical trials for patients with cutaneous squamous cell carcinoma. It is also developing RP2, which is in Phase I clinical trials for an anti-CTLA-4 antibody-like protein in order to block the inhibition of the immune response otherwise caused by CTLA-4; and RP3 that is in Phase I clinical trials to express immune-activating proteins that stimulate T cells. Replimune Group, Inc. was founded in 2015 and is headquartered in Woburn, Massachusetts.
CEO: Astley-Sparke FSA, Philip
Market: NASDAQ
Futu Hot List
USHKCN
TradeSearchNews
SymbolLatest price%Chg

Loading...

Watchlist
Back to the Top